Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Heinz WiendlTimothy SpelmanHelmut ButzkuevenLudwig KapposMaria TrojanoRay SuNolan CampbellPei-Ran HoStephanie LicataPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)
These results highlight disability improvement as a potential benefit of natalizumab treatment. Improvements across all FS demonstrate the range of functional improvement.